RNA Vaccines: Quality Concepts in GMP IVT mRNA Development, Manufacturing & Analytics

mRNA vaccines rapidly gained the spotlight during recent years as a result of the COVID-19 pandemic and their quick implementation in response to SARS-CoV2 virus. The core molecular technologies of these therapeutics have been in development for decades in various forms and are now following breakthroughs that overcame some of the initial challenges, moving rapidly from R&D benchtops to GMP clinical development and front-line patient treatment.

As such, quality systems, compliance principles, process controls and analytics must keep pace and adapt to this new class of therapeutics. While production of mRNA therapeutics shares many of the key quality considerations as established for other larger molecule therapies, the methods of production and determination of key quality attributes are still emerging and are specific to the new technologies and evolving in step with research and technological advances in the field.

This webinar will provide a general overview of mRNA therapeutics design and production and discuss the importance of robust quality systems in the context of GMP production of mRNA therapeutics. The speaker will focus control of raw materials used in production, identification of appropriate quality control testing methods for release and stability and analytical method development specific to the production and evaluation of bulk mRNA drug substance or intermediate.

Join today for a review of the quality concepts in the development of mRNA vaccines, especially in the context of GMP IVT mRNA development, manufacturing and analytics.